Petley, Emma V.
Koay, Hui-Fern http://orcid.org/0000-0002-3236-9609
Henderson, Melissa A.
Sek, Kevin http://orcid.org/0000-0003-4634-7600
Todd, Kirsten L.
Keam, Simon P.
Lai, Junyun
House, Imran G. http://orcid.org/0000-0002-6245-5954
Li, Jasmine
Zethoven, Magnus
Chen, Amanda X. Y.
Oliver, Amanda J.
Michie, Jessica
Freeman, Andrew J. http://orcid.org/0000-0003-0040-5617
Giuffrida, Lauren
Chan, Jack D. http://orcid.org/0000-0002-5942-8592
Pizzolla, Angela http://orcid.org/0000-0003-2024-4144
Mak, Jeffrey Y. W. http://orcid.org/0000-0002-8011-4539
McCulloch, Timothy R. http://orcid.org/0000-0003-0247-7374
Souza-Fonseca-Guimaraes, Fernando
Kearney, Conor J.
Millen, Rosemary
Ramsay, Robert G.
Huntington, Nicholas D. http://orcid.org/0000-0002-5267-7211
McCluskey, James http://orcid.org/0000-0002-8597-815X
Oliaro, Jane http://orcid.org/0000-0002-2097-6428
Fairlie, David P. http://orcid.org/0000-0002-7856-8566
Neeson, Paul J. http://orcid.org/0000-0002-2729-5887
Godfrey, Dale I. http://orcid.org/0000-0002-3009-5472
Beavis, Paul A. http://orcid.org/0000-0002-2116-013X
Darcy, Phillip K. http://orcid.org/0000-0002-5303-9561
Article History
Received: 28 July 2020
Accepted: 19 July 2021
First Online: 6 August 2021
Competing interests
: J.M. and D.P.F. are named inventors on a patent application (PCT/AU2013/000742, WO2014005194) and J.Y.W.M., J.M. and D.P.F. are named inventors on another patent application (PCT/AU2015/050148, WO2015149130) involving MR1 ligands for MR1-restricted MAIT cells owned by University of Queensland, Monash University and University of Melbourne. A.P. current position is supported by Roche-Genentech. N.D.H. is co-founder, shareholder, and advisor of oNKo-Innate Pty Ltd. P.J.N. has research funding from BMS, Roche Genentech, Compugen, and Allergan. F.S.F.G. is a consultant and has funded research agreements with Biotheus Inc. P.K.D. declares the following conflicts: research funding from Myeloid Therapeutics, Prescient Therapeutics and Juno Therapeutics. P.A.B. declares the following conflicts: research funding from AstraZeneca, Bristol-Myers Squibb, and Gilead Sciences. The remaining authors declare no competing interests.